BBIO

Bridgebio Pharma

• Benzinga·1d ago

  BridgeBio Pharma Files Prospectus Related To Offer And Sale Of Up To 24.6M Common Shares By Selling Stockholders

• TipRanks·1d ago

  BridgeBio files to sell 24.63M shares of common stock for holders

• Reuters·1d ago

  BRIDGEBIO PHARMA INC: FILES FOR OFFERING OF UP TO 24.6 MLN COMMON SHARES BY SELLING STOCKHOLDERS - SEC FILING

• TipRanks·2d ago

  Analyst Reiterates Buy on BridgeBio, Maintaining $120 Price Target as Late-Stage Rare Disease Pipeline Advances

• Simply Wall St·2d ago

  Is FDA’s Encaleret NDA Acceptance Redefining the Investment Case For BridgeBio Pharma (BBIO)?

• TipRanks·3d ago

  BridgeBio’s Encaleret NDA Accepted by U.S. FDA

• TipRanks·3d ago

  BridgeBio: Buy Rating Reaffirmed on Strong Encaleret Data and Multi‑Asset Launch Outlook

• Seeking Alpha·3d ago

  BridgeBio granted FDA review for hypoparathyroidism therapy

• Benzinga·3d ago

  BridgeBio Pharma Announces FDA Accepts For Filing Its New Drug Application For Encaleret To Treat Autosomal Dominant Hypocalcemia Type 1

• PUBT·3d ago

  BridgeBio says FDA accepts encaleret NDA for ADH1, sets May 8, 2027 PDUFA date

• Reuters·3d ago

  BRIDGEBIO PHARMA - TO INITIATE RECLAIM-HP PHASE 3 STUDY OF ENCALERET IN CHRONIC HYPOPARATHYROIDISM

• Reuters·6d ago

  BRIDGEBIO PHARMA INC <BBIO.O>: JEFFERIES RAISES TARGET PRICE TO $110 FROM $100

• Simply Wall St·6d ago

  BridgeBio Pharma (BBIO) Faces A Valuation Test As Pipeline Optimism Builds

• Barron‘s·07/17 20:11

  Yext, Mission Produce, and 3 More Stocks See Action From Activist Investors

• Dow Jones·07/16 20:30

  BridgeBio Pharma Is Maintained at Neutral by Citigroup